Acetylcholine esterase activity in mild cognitive impairment and Alzheimer's disease

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue SUPPL. 1, 2008, Pages

  Herholz, Karl ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Acetylcholine esterase; Alzheimer's disease; Mild cognitive impairment; Neurodegenerative disease; Positron emission tomography

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; N METHYL 4 PIPERIDYL ACETATE C 11; N METHYL 4 PIPERIDYL PROPIONATE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; COGNITIVE DEFECT; ENZYME ACTIVITY; HUMAN; IN VIVO STUDY; MILD COGNITIVE IMPAIRMENT; PARASYMPATHETIC INNERVATION; POSITRON EMISSION TOMOGRAPHY; REVIEW;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; BRAIN; COGNITION DISORDERS; DIAGNOSTIC IMAGING; ENZYME ACTIVATION; HUMANS; MODELS, NEUROLOGICAL; MOLECULAR PROBE TECHNIQUES; TISSUE DISTRIBUTION;

EID: 41149114057     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0699-4     Document Type: Review

References (43)

1. Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 1999;22:273-80.
2. Mesulam M. The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? Learn. Mem. 2004;11:43-9.
3. Sarter M, Hasselmo ME, Bruno JP, Givens B. Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection. Brains Res Rev. 2005;48:98-111.
4. Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, Perl DP, Schmeidler J, Kanof P, Davis KL. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem. 1995;64:749-60.
5. Reinikainen KJ, Soininen H, Riekkinen PJ. Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy. J Neurosci Res. 1990;27:576-86.
6. Auld DS, Kornecook TJ, Bastianetto S, Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to [beta]-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol. 2002;68:209-45.
7. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 1999;281:1401-6.
8. DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, Cochran EJ, Kordower JH, Mufson EJ. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002;51:145-55.
9. Gilmor ML, Erickson JD, Varoqui H, Hersh LB, Bennett DA, Cochran EJ, Mufson EJ, Levey AI. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol. 1999;411:693-704.
10. Mesulam MM, Geula C. Acetylcholinesterase-rich neurons of the human cerebral cortex: cytoarchitectonic and ontogenetic patterns of distribution. J Comp Neurol. 1991;306:193-220.
11. Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol. 1978;4:273-7.
12. Inestrosa NC, Alarcon R. Molecular interactions of acetylcholinesterase with senile plaques. J Physiol Paris. 1998;92:341-4.
13. Namba H, Irie T, Fukushi K, Iyo M. In vivo measurement of acetylcholinesterase activity in the brain with a radioactive acetylcholine analog. Brain Res. 1994;667:278-82.
14. Kilbourn MR, Snyder SE, Sherman PS, Kuhl DE. In vivo studies of acetylcholinesterase activity using a labeled substrate, n-[C-11]methylpiperdin- 4-yl propionate ([C-11]PMP). Synapse. 1996;22:123-31.
15. Koeppe RA, Frey KA, Snyder SE, Meyer P, Kilbourn MR, Kuhl DE. Kinetic modeling of N-[11C]methylpiperidin-4-yl propionate: alternatives for analysis of an irreversible positron emission tomography trace for measurement of acetylcholinesterase activity in human brain. J Cereb Blood Flow Metab. 1999;19:1150-63.
16. Shinotoh H, Fukushi K, Nagatsuka S, Irie T. Acetylcholinesterase imaging: its use in therapy evaluation and drug design. Curr Pharm Des. 2004;10:1505-17.
17. Shinotoh H, Namba H, Fukushi K, Nagatsuka S, Tanaka N, Aotsuka A, Tanada S, Irie T. Brain acetylcholinesterase activity in Alzheimer disease measured by positron emission tomography. Alzheimer Dis Assoc Disord. 2000;14(Suppl 1):S114-8.
18. Herholz K, Bauer B, Wienhard K, Kracht L, Mielke R, Lenz O, Strotmann T, Heiss WD. In-vivo measurements of regional acetylcholine esterase activity in degenerative dementia: comparison with blood flow and glucose metabolism. J Neural Transm. 2000;12:1457-68.
19. Namba H, Iyo M, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T, Sudo Y, Suzuki K, Irie T. Human cerebral acetylcholinesterase activity measured with positron emission tomography: procedure, normal values and effect of age. Eur J Nucl Med. 1999;26:135-43.
20. Atack JR, Perry EK, Bonham JR, Candy JM, Perry RH. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem. 1986;47:263-77.
21. Herholz K, Lercher M, Wienhard K, Bauer B, Lenz O, Heiss WD. PET measurement of cerebral acetylcholine esterase activity without blood sampling. Eur J Nucl Med. 2001;28:472-7.
22. Zundorf G, Herholz K, Lercher M, Wienhard K, Bauer B, Weisenbach S, Heiss WD. In: Senda M, Kimura Y, Herscovitch P, editors. PET functional parametric images of acetylcholine esterase activity without blood sampling Brain imaging using PET. San Diego, CA.: Academic; 2002. p. 41-6.
23. Nagatsuka S, Fukushi K, Shinotoh H, Namba H, Iyo M, Tanaka N, Aotsuka A, Ota T, Tanada S, Irie T. Kinetic analysis of [(11)C]MP4A using a high-radioactivity brain region that represents an integrated input function for measurement of cerebral acetylcholinesterase activity without arterial blood sampling. J Cereb Blood Flow Metab. 2001;21:1354-66.
24. Sato K, Fukushi K, Shinotoh H, Nagatsuka S, Tanaka N, Aotsuka A, Ota T, Shiraishi T, Tanada S, Iyo M, Irie T. Evaluation of simplified kinetic analyses for measurement of brain acetylcholinesterase activity using N-[11C]Methylpiperidin-4-yl propionate and positron emission tomography. J Cereb Blood Flow Metab. 2004;24:600-11.
25. Huff FJ, Reiter CT, Rand JB. The ratio of acetylcholinesterase to butyrylcholinesterase influences the specificity of assays for each enzyme in human brain. J Neural Transm. 1989;75:129-34.
26. Roivainen A, Rinne J, Virta J, Jarvenpaa T, Salomaki S, Yu M, Nagren K. Biodistribution and blood metabolism of 1-11C-methyl-4-piperidinyl n-butyrate in humans: an imaging agent for in vivo assessment of butyrylcholinesterase activity with PET. The J Nucl Med. 2004;45:2032-9.
27. Snyder SE, Gunupudi N, Sherman PS, Butch ER, Skaddan MB, Kilbourn MR, Koeppe RA, Kuhl DE. Radiolabeled cholinesterase substrates: in vitro methods for determining structure-activity relationships and identification of a positron emission tomography radiopharmaceutical for in vivo measurement of butyrylcholinesterase activity. J Cereb Blood Flow Metab. 2001;21:132-43.
28. Traykov L, Tavitian B, Jobert A, Boller F, Forette F, Crouzel C, Di Giamberardino L, Pappata S. In vivo PET study of cerebral [11C] methyl-tetrahydroaminoacridine distribution and kinetics in healthy human subjects. Eur J Neurol. 1999;6:273-8.
29. Funaki Y, Kato M, Iwata R, Sakurai E, Sakurai E, Tashiro M, Ido T, Yanai K. Evaluation of the binding characteristics of [5-(11)C-methoxy]donepezil in the rat brain for in vivo visualization of acetylcholinesterase. J Pharmacol Sci. 2003;91:105-12.
30. De Vos F, Santens P, Vermeirsch H, Dewolf I, Dumont F, Slegers G, Dierckx RA, De Reuck J. Pharmacological evaluation of [11C]donepezil as a tracer for visualization of acetylcholinesterase by PET. Nucl Med Biol. 2000;27:745-7.
31. Bencherif B, Endres CJ, Musachio JL, Villalobos A, Hilton J, Scheffel U, Dannals RF, Williams S, Frost JJ. PET imaging of brain acetylcholinesterase using [11C]CP-126,998, a brain selective enzyme inhibitor. Synapse. 2002;45:1-9.
32. Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, Frey KA, Kilbourn MR. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology. 1999;52:691-9.
33. Iyo M, Namba H, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T, Sudo Y, Suzuki K, Irie T. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimers disease. Lancet. 1997;349:1805-9.
34. Rinne JO, Kaasinen V, Jarvenpaa T, Nagren K, Roivainen A, Yu M, Oikonen V, Kurki T. Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003;74:113-5.
35. Herholz K, Weisenbach S, Zundorf G, Lenz O, Schroder H, Bauer B, Kalbe E, Heiss WD. In-vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease. Neuroimage. 2004;21:136-43.
36. Shinotoh H, Fukushi K, Nagatsuka S, Tanaka N, Aotsuka A, Ota T, Namba H, Tanada S, Irie T. The amygdala and Alzheimer's disease: positron emission tomographic study of the cholinergic system. Ann NY Acad Sci. 2003;985:411-9.
37. Eggers C, Herholz K, Kalbe E, Heiss WD. Cortical acetylcholine esterase activity and ApoE4-genotype in Alzheimer disease. Neurosci Lett. 2006;408:46-50.
38. Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, Mathis CA, Moore RY, DeKosky ST. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol. 2003;60:1745-8.
39. Herholz K, Weisenbach S, Kalbe E, Diederich NJ, Heiss WD. Cerebral acetylcholine esterase activity in mild cognitive impairment. Neuroreport. 2005;16:1431-4.
40. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Koeppe RA, Meltzer CC, Constantine G, Davis JG, Mathis CA, DeKosky ST, Moore RY. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2005;76:315-9.
41. Kaasinen V, Nagren K, Jarvenpaa T, Roivainen A, Yu M, Oikonen V, Kurki T, Rinne JO. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol. 2002;22:615-20.
42. Kadir A, Darreh-Shori T, Almkvist O, Wall A, Grut M, Strandberg B, Ringheim A, Eriksson B, Blomquist G, Langstrom B, Nordberg A. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiol Aging. 2007 (in press). http://dx.doi.org/10.1016/j.neurobiolaging.2007.02.020
43. Kadir A, Almkvist O, Wall A, Langstrom B, Nordberg A. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology (Berl). 2006;188:509-20.